Affiliation: Johns Hopkins University
- Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesisDonger Zhou
The Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, the Key Laboratory of Molecular Biology in Medical Sciences of Zhejiang Province, Cancer Institute, Hangzhou, Zhejiang, China
PLoS ONE 8:e53310. 2013..Thus, the comparison of genomic mutations between adenoma and adenocarcinoma provides us a new insight into the molecular events governing the early step of colorectal tumorigenesis...
- Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinomaLei Zheng
The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Gastroenterology 144:1230-40. 2013..Unlike single therapeutic agent studies that block immunosuppressive mechanisms, studies of combination therapies that include therapeutic vaccines have provided promising results...
- Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancerLei Zheng
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
PLoS ONE 6:e19390. 2011..Thus, ANXA2 is part of a novel molecular pathway underlying PDA metastases and a new target for development of PDA therapeutics...
- Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerDung T Le
The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
J Immunother 36:382-9. 2013..014) and enhancement of the T-cell repertoire (P = 0.031). In conclusion, checkpoint blockade in combination with GVAX has the potential for clinical benefit and should be evaluated in a larger study...
- Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancerJoseph M Herman
Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Int J Radiat Oncol Biol Phys 86:678-85. 2013..Gemcitabine-erlotinib therapy has demonstrated a survival benefit for patients with metastatic PDAC. Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC...
- PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumorsKevin C Soares
Departments of Oncology Pathology Surgery The Sidney Kimmel Cancer Center The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD Amplimmune Inc, Gaithersburg, MD Department of Surgery, University of Colorado School of Medicine, Aurora, CO
J Immunother 38:1-11. 2015..Collectively, our study supports combining PD-1 or PD-L1 antibody therapy with a T cell inducing agent for PDA treatment. ..
- Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancerSiva P Raman
1 Department of Radiology, Johns Hopkins University School of Medicine, JHOC 3251, 601 N Caroline St, Baltimore, MD 21287
AJR Am J Roentgenol 204:W37-42. 2015..This study examines the relationship between the interval between imaging and surgery and the accuracy of MDCT in determining the presence or absence of metastatic disease at surgery in patients with pancreatic cancer...
- A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancerLei Zheng
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Ann Surg Oncol 21:3931-7. 2014..Preclinical studies have supported the antitumor activity of immunization with a granulocyte-macrophage colony-stimulating factor (GM-CSF) producing murine colon tumor cell vaccine...
- Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccineAaron J Schueneman
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Ann Surg Oncol 20:S725-30. 2013..Although immune-based therapies are under rapid development, it is not known whether baseline complete blood counts, particularly lymphocytes, are associated with the clinical outcomes of patients receiving immunotherapies...
- Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinomaPriya Mathews
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Ann Surg Oncol 20:1216-22. 2013..To determine whether the genomic changes in hepatitis B virus (HBV) affect the clinical outcomes of hepatocellular carcinoma (HCC) in patients with HBV-associated HCC treated with curative surgical resection...
- Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationEric R Lutz
Authors Affiliations Departments of Oncology, The Sidney Kimmel Cancer Center The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland and
Cancer Immunol Res 2:616-31. 2014....
- Multidisciplinary management of pancreatic cancerRachit Kumar
Department of Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Surg Oncol Clin N Am 22:265-87. 2013..In this review, the importance of multidisciplinary management of pancreatic cancer based on disease stage is discussed...
- Young patients undergoing resection of pancreatic cancer fare better than their older counterpartsJin He
Department of Surgery, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD 21287, USA
J Gastrointest Surg 17:339-44. 2013..We investigated features of PDAC occurring in young patients (≤45 years) who underwent surgical resection in order to determine if any difference exists in comparison to elderly patients (≥70 years)...
- Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerDarshil T Jhaveri
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center and the Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
Semin Oncol 41:559-75. 2014..A combinatorial approach simultaneously targeting antigens on the PDA cell, stroma, and immunosuppressive cells should be employed. ..
- A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinomaAna De Jesus-Acosta
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Baltimore, MD 21231, USA
Cancer Chemother Pharmacol 69:415-24. 2012..We were interested in determining the clinical benefit of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma...